



Contract Research Organisation signed for HERACLES trial

Highlights

- Australian contract research organisation (CRO) with extensive experience
- Provider of important services
- Momentum builds for clinical trial

Sydney, 4 December 2024: Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce it has engaged a highly experienced Australian contract research organisation (CRO) to provide a wide range of services to support the upcoming [HERACLES clinical trial](#).

These include trial and data management, pharmacovigilance (drug safety), statistical analysis, and medical writing of post-trial reporting.

The CRO is a trusted service provider, having previously worked with Noxopharm, and has over three decades of experience in the field. It has managed clinical research across all phases, and most therapeutic areas, for both early phase clinical trials and late phase studies.

It will play a central role in ensuring the trial runs efficiently, and that robust and reliable data is produced at key milestones.

Noxopharm CEO Dr Gisela Mautner said: “Bringing an experienced CRO on board is another essential step forward in building the team that will support the HERACLES trial. We have already worked with them and know the high-quality services they can deliver.

“In addition, we are currently moving ahead with selecting a Phase 1 unit for the trial and expect this to be completed in due course.”

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US registered, Australia based Nyrada Inc (ASX: NYR), a drug discovery and development company specialising in novel small molecule therapies.

To learn more, please visit: noxopharm.com

**Investor, Corporate & Media enquiries:**

Julian Elliott

M: 0425 840 071

E: julian.elliott@noxopharm.com**Company Secretary:**

David Franks

T: +61 2 8072 1400

E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.